Coronary Artery Disease
Conditions
Interventions
Group 2:5% glucose injection
Sponsors
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years, no gender limit; 2. Meet the diagnostic criteria for ischemic cardiomyopathy and have symptoms of heart failure; 3. Patients with grade 2 /3 cardiac function; 4. Left ventricular ejection fraction was less than 45%; 5. Agree to participate in the clinical trial and sign a written informed consent before surgery.
Exclusion criteria
Exclusion criteria: 1. Patients with acute myocardial infarction; 2. Receiving coenzyme I or other myocardial nutritional drugs (e.g., trimetazidine, coenzyme Q10, L-carnitine, phosphocreatine, renozine) 30 days before the start of the experiment or during hospitalization; 3. History of trauma within 2 months, including traumatic cardiopulmonary resuscitation or prolonged cardiopulmonary resuscitation (>=10min), or major surgical operations; History of head trauma within 6 months; 4. Patients with uncontrolled hypertension (systolic blood pressure >=180mmHg and/or diastolic blood pressure >=110mmHg); 5. Patients with previous congenital/valvular heart disease; 6. History of severe hepatic and renal dysfunction (AST/ALT more than 3 times the upper limit of normal value; Creatinine >=225µmol/L); 7. Patients with severe diseases, such as malignant tumor, lymphoma, cirrhosis, HIV positive, etc., whose life expectancy is less than 1 year; 8. History of active hemorrhage, intracranial hemorrhage, major surgery or trauma within 1 month, ischemic stroke or TIA within 6 months; 9. Patients with multi-vessel lesions of non-target vessels are scheduled to be intervened within 7 days (simultaneous or multiple times); 10. CABG was proposed within 1 month after screening; 11. Patients who are pregnant or preparing to become pregnant or lactating; 12. Known allergy or severe adverse reactions to coenzyme I injection and its components; 13. Participated in other clinical trials within 3 months prior to the study; 14. In the investigator's judgment, the patient is unable to complete the study or comply with the requirements of the study; 15. Participating in other interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction; | — |
Countries
China
Contacts
Public ContactMa Likun
Outcome results
None listed